Literature DB >> 22605980

Toward the understanding of the metabolism of levodopa I. DFT investigation of the equilibrium geometries, acid-base properties and levodopa-water complexes.

Shabaan A K Elroby1,2, Mohamed S I Makki1, Tariq R Sobahi1, Rifaat H Hilal1,3.   

Abstract

Levodopa (LD) is used to increase dopamine level for treating Parkinson's disease. The major metabolism of LD to produce dopamine is decarboxylation. In order to understand the metabolism of LD; the electronic structure of levodopa was investigated at the Density Functional DFT/B3LYP level of theory using the 6-311+G** basis set, in the gas phase and in solution. LD is not planar, with the amino acid side chain acting as a free rotator around several single bonds. The potential energy surface is broad and flat. Full geometry optimization enabled locating and identifying the global minimum on this Potential energy surface (PES). All possible protonation/deprotonation forms of LD were examined and analyzed. Protonation/deprotonation is local in nature, i.e., is not transmitted through the molecular framework. The isogyric protonation/deprotonation reactions seem to involve two subsequent steps: First, deprotonation, then rearrangement to form H-bonded structures, which is the origin of the extra stability of the deprotonated forms. Natural bond orbital (NBO) analysis of LD and its deprotonated forms reveals detailed information of bonding characteristics and interactions across the molecular framework. The effect of deprotonation on the donor-acceptor interaction across the molecular framework and within the two subsystems has also been examined. Attempts to mimic the complex formation of LD with water have been performed.

Entities:  

Keywords:  DFT; NBO; levodopa; parkinson’s disease; protonation/deprotonation

Mesh:

Substances:

Year:  2012        PMID: 22605980      PMCID: PMC3344216          DOI: 10.3390/ijms13044321

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   6.208


  29 in total

1.  Density-functional exchange-energy approximation with correct asymptotic behavior.

Authors: 
Journal:  Phys Rev A Gen Phys       Date:  1988-09-15

2.  Fluorometric determination of methyldopa in biological fluids.

Authors:  B K Kim; R T Koda
Journal:  J Pharm Sci       Date:  1977-11       Impact factor: 3.534

3.  Metabolism of 3,4-dihydroxyphenylalanine (L-dopa) in human subjects.

Authors:  M Goodall; H Alton
Journal:  Biochem Pharmacol       Date:  1972-09-01       Impact factor: 5.858

4.  Metabolism of 3,4-dihydroxyphenylalanine by isolated perfused rat liver.

Authors:  G M Tyce
Journal:  Biochem Pharmacol       Date:  1971-12       Impact factor: 5.858

5.  The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport.

Authors:  J G Nutt; W R Woodward; J P Hammerstad; J H Carter; J L Anderson
Journal:  N Engl J Med       Date:  1984-02-23       Impact factor: 91.245

6.  Reversed-phase high-performance liquid chromatography of catecholamines and indoleamines using a simple gradient solvent system and native fluorescence detection.

Authors:  A T Wood; M R Hall
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2000-07-07

7.  Simultaneous determination of L-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection.

Authors:  F Blandini; E Martignoni; C Pacchetti; S Desideri; D Rivellini; G Nappi
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1997-10-24

8.  3-O-methyldopa blocks dopa metabolism in rat corpus striatum.

Authors:  A Reches; S Fahn
Journal:  Ann Neurol       Date:  1982-09       Impact factor: 10.422

9.  A specific radioenzymatic assay for dihydroxyphenylalanine (DOPA). Plasma dopa may be the precursor of urine free dopamine.

Authors:  M J Brown; C T Dollery
Journal:  Br J Clin Pharmacol       Date:  1981-01       Impact factor: 4.335

10.  Urinary free methyldopa determined by reversed-phase high-performance liquid chromatography.

Authors:  L D Mell; A B Gustafson
Journal:  Clin Chem       Date:  1978-01       Impact factor: 8.327

View more
  1 in total

1.  Serum B12, Homocysteine Levels, and their Effect on Peripheral Neuropathy in Parkinson's Disease: Indian Cohort.

Authors:  Neeharika L Mathukumalli; Mridula R Kandadai; Jabeen A Shaik; Meena A Kanikannan; Rupam Borgohain
Journal:  Ann Indian Acad Neurol       Date:  2020 Jan-Feb       Impact factor: 1.383

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.